Intas Biopharmaceuticals Ltd. Acquires US-based BPD Inc.

SAN DIEGO--(Business Wire)--
India's leading biopharmaceutical company, Intas
Biopharmaceuticals Ltd. (IBPL, www.intasbiopharma.co.in), has acquired
US-based biotechnology corporation, Biologics Process Development
Incorporated (BPD Inc., www.biologicspd.com), based in Poway,
California. With the acquisition process underway, both Intas
Biopharma and BPD Inc. are actively pursuing plans to work closely
toward fulfillment of common business objectives in the area of
biologics Contract Research and Manufacturing Services (CRAMS).

This development will facilitate and assist Intas Biopharma's
foray into the US market especially to expand its CRAMS business. With
mutual understanding and agreement between the two companies, Dr.
Scott M. Brown, Founder, President and Chief Scientific Officer of
BPD, Inc., will continue as President and Chief Scientific Officer.

Expressing his view on the development, Dr. Brown said, "We are
pleased to become associates with Intas Biopharmaceuticals, a leader
in the area of biologics research and manufacturing in India. Jointly
we complement each other on the technology front, and we at BPD Inc.
are looking forward to working with Intas and exploring new technology
frontiers."

Intas Biopharma's venture into the CRAMS business has opened up
new vistas for R&D in the area of biopharmaceuticals and biosimilars.
According to Dr. Dhananjay Patankar, CTO of Intas Biopharmaceuticals
Ltd., "IBPL has taken up the CRAMS opportunity in the biotechnology
space as a focus area with tremendous potential and is preparing to
scale up its facilities. IBPL offers a unique business model for
offshore clients, providing competitive advantages in terms of
developing new biotech products, technology transfer and contract
manufacturing in a seamless manner and at committed costs, quality,
and time."

Biologics Process Development, Inc.
Dr. Scott M. Brown, 858-486-9850
smbrown@biologicspd.com
or
Intas Biopharmaceuticals Ltd.
Mr. Mani Iyer, +91 2717 660 100
mani.iyer@intasbiopharma.co.in

Copyright Business Wire 2008